GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InSite Vision Inc (OTCPK:INSV) » Definitions » Cyclically Adjusted Price-to-FCF

InSite Vision (InSite Vision) Cyclically Adjusted Price-to-FCF : (As of May. 25, 2024)


View and export this data going back to . Start your Free Trial

What is InSite Vision Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


InSite Vision Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for InSite Vision's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InSite Vision Cyclically Adjusted Price-to-FCF Chart

InSite Vision Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

InSite Vision Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of InSite Vision's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, InSite Vision's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InSite Vision's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InSite Vision's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where InSite Vision's Cyclically Adjusted Price-to-FCF falls into.



InSite Vision Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

InSite Vision's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2015 is calculated as:

For example, InSite Vision's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2015 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jun. 2015 (Change)*Current CPI (Jun. 2015)
=-0.039/100.6839*100.6839
=-0.039

Current CPI (Jun. 2015) = 100.6839.

InSite Vision Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200509 -0.044 83.876 -0.053
200512 -0.039 83.032 -0.047
200603 -0.075 84.298 -0.090
200606 -0.049 85.606 -0.058
200609 -0.032 85.606 -0.038
200612 -0.034 85.142 -0.040
200703 0.103 86.640 0.120
200706 0.136 87.906 0.156
200709 -0.031 87.964 -0.035
200712 -0.044 88.616 -0.050
200803 -0.059 90.090 -0.066
200806 -0.088 92.320 -0.096
200809 -0.077 92.307 -0.084
200812 -0.093 88.697 -0.106
200903 -0.065 89.744 -0.073
200906 -0.030 91.003 -0.033
200909 -0.018 91.120 -0.020
200912 -0.021 91.111 -0.023
201003 -0.026 91.821 -0.029
201006 -0.022 91.962 -0.024
201009 -0.028 92.162 -0.031
201012 -0.012 92.474 -0.013
201103 -0.029 94.283 -0.031
201106 -0.017 95.235 -0.018
201109 -0.025 95.727 -0.026
201112 -0.012 95.213 -0.013
201203 -0.031 96.783 -0.032
201206 -0.036 96.819 -0.037
201209 0.004 97.633 0.004
201212 -0.016 96.871 -0.017
201303 -0.019 98.209 -0.019
201306 0.097 98.518 0.099
201309 -0.004 98.790 -0.004
201312 -0.002 98.326 -0.002
201403 -0.022 99.695 -0.022
201406 0.024 100.560 0.024
201409 -0.016 100.428 -0.016
201412 -0.026 99.070 -0.026
201503 -0.005 99.621 -0.005
201506 -0.039 100.684 -0.039

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


InSite Vision  (OTCPK:INSV) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


InSite Vision Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of InSite Vision's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


InSite Vision (InSite Vision) Business Description

Traded in Other Exchanges
N/A
Address
InSite Vision Inc was incorporated in 1986 as a California Corporation and reincorporated in Delaware in 1987. The Company is an ophthalmic product development company committed to advancing ophthalmic pharmaceutical products to address unmet eye care needs. The Company completed its initial public offering on October 18, 1993. The Company's current portfolio of ophthalmic pharmaceutical products is based on its proprietary DuraSite drug delivery technology. The Company's DuraSite sustained drug delivery technology is a proven, patented synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. It enables topical delivery of a solution, gel or suspension and could be customized for delivering a variety of potential drug candidates. The Company has focused its research, development and commercial support efforts on the following topical products formulated with its DuraSite drug delivery technology. AzaSite or azithromycin ophthalmic solution 1% is a DuraSite formulation of azithromycin developed as a broad spectrum ocular antibiotic and approved by the U.S. Food and Drug Administration in April 2007 to treat bacterial conjunctivitis. Additional indications are being pursued by Inspire Pharmaceuticals for this product. AzaSite was commercially launched in the United States by Inspire Pharmaceuticals in August 2007. DexaSite is a DuraSite formulation of dexamethasone in development for the treatment of ocular inflammation. In November 2011, it initiated a Phase 3 clinical trial for this product candidate in blepharitis and completed patient enrollment in the clinical trial in September 2012. BromSite is a DuraSite formulation of bromfenac in development for the prevention of post-operative inflammation and eye pain. It initiated a Phase 1/2 clinical trial for this product candidate in August 2010 and received positive top-line results from this study in the first quarter of 2011, which demonstrated the efficacy and safety of BromSite. DuraSite 2 is a next-generation enhanced drug delivery system, which is designed to provide a broad platform for developing superior ophthalmic therapeutics. DuraSite 2 is based on the original DuraSite technology, and incorporates a cationic polymer to achieve sustained and enhanced ocular delivery of drugs. ISV-101 is a DuraSite formulation with a low concentration of bromfenac for the treatment of dry eye disease. The Company is subject to regulation by numerous governmental authorities in the United States and other countries.
Executives
Louis Drapeau officer: Vice President and CFO C/O BIOMARIN PHARMACEUTICAL INC., 371 BEL MARIN KEYS BLVD., SUITE 210, NOVATO CA 94949
Brian Levy director
Anthony J Yost director C/O INSITE VISION, INC., 965 ATLANTIC AVENUE, ALAMEDA CA 94501
Timothy Mcinerney director
Craig A Tooman director
Coliseum Capital Management, Llc 10 percent owner 105 ROWAYTON AVENUE, ROWAYTON CT 06853
Timothy P Lynch director 919 NW BOND STREET, SUITE 204, BEND OR 97703
Rick D Anderson director 3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746
Jon S Saxe director FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Francis Wen-hou Chen director 1821 JONES STREET, SAN FRANCISCO CA 94109
Pinto Tv Gp Co Llc 10 percent owner 3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746
Matthew S Crawford 10 percent owner 3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746
Pfizer Inc 10 percent owner 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192

InSite Vision (InSite Vision) Headlines

No Headlines